CMB.TECH Sells Two Suezmaxes, Adds $100.5M Capital Gain – Asset-Sale Dependency Continues

What happened

CMB.TECH sold two Suezmaxes for a ~$100.5M capital gain, continuing its pattern of asset monetization to fund growth and service debt. This follows the $269.2M gain from eight vessels in January 2026 and the $635M in gains that underpinned 2024's record profit. While such sales showcase hidden asset value and provide near-term cash, they are non-recurring and underscore the company's dependence on transactional income rather than sustainable operations. The report rates CMBT a WAIT with a $14 base case, noting that earnings volatility and high leverage (~2.2x debt/equity, 4.8x net debt/EBITDA) leave little room for market or execution missteps. This sale does not alter the thesis but reinforces the need to track whether EBITDA growth from the ~$3B backlog can outpace rising finance costs and eventually reduce reliance on asset sales.

Implication

The sale provides temporary funding flexibility but does not address the structural challenge: CMBT must convert its ~$3B backlog into recurring EBITDA to cover rising interest costs and delever. Without sustained operational improvement, continued asset sales may shrink the fleet and erode future earning power. Investors should wait for evidence that 2026 deliveries and ammonia projects start generating cash flow before considering a position.

Thesis delta

No material shift in thesis. The asset sale is consistent with the company's funding strategy and does not alter the risk/reward calculus. The key uncertainties remain: (i) whether $3B backlog converts to EBITDA growth, (ii) whether ammonia infrastructure ramps on schedule, and (iii) whether leverage stabilizes. The news reinforces the need to monitor these checkpoints, not change the call.